<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39377176</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1750-2659</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Influenza and other respiratory viruses</Title><ISOAbbreviation>Influenza Other Respir Viruses</ISOAbbreviation></Journal><ArticleTitle>Enhancing Omicron Sublineage Neutralization: Insights From Bivalent and Monovalent COVID-19 Booster Vaccines and Recent SARS-CoV-2 Omicron Variant Infections.</ArticleTitle><Pagination><StartPage>e70000</StartPage><MedlinePgn>e70000</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e70000</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1111/irv.70000</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Omicron variants have rapidly diversified into sublineages with mutations that enhance immune evasion, posing challenges for vaccination and antibody responses. This study aimed to compare serum cross-neutralizing antibody responses against various SARS-CoV-2 Omicron sublineages (BA.1, BA.5, XBB.1.17.1, FK.1.1, and JN.1) in recipients of monovalent COVID-19 boosters, bivalent booster recipients, and individuals who had recovered from Omicron BA.5 infections.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a micro-neutralization assay on serum samples from monovalent BNT162b2 booster recipients (N = 54), bivalent BNT162b2 booster recipients (N = 24), and SARS-CoV-2 Omicron BA.5-recovered individuals (N = 13). The history of SARS-CoV-2 Omicron infection was assessed using ELISA against the SARS-CoV-2 NP protein.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Bivalent booster recipients exhibited significantly enhanced neutralization efficacy against Omicron sublineages compared to those who had received monovalent booster vaccinations. Omicron BA.5-recovered individuals displayed similar neutralizing antibodies (NAbs) to the bivalent booster recipients. Despite the improved neutralization in bivalent recipients and BA.5-recovered individuals, there were limitations in neutralization against the recently emerged Omicron subvariants: XBB.1.17.1 FK.1.1, and JN.1. In both monovalent and bivalent booster recipients, a history of Omicron breakthrough infection was associated with relatively higher geometric mean titers of NAbs against Omicron BA.1, BA.5, and XBB.1.17.1 variants.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study underscores the intricate interplay between vaccination strategies, immune imprinting, and the dynamic landscape of SARS-CoV-2 variants. Although bivalent boosters enhance neutralization, addressing the challenge of emerging sublineages like XBB.1.17.1, FK.1.1, and JN.1 may necessitate the development of tailored vaccines, underscoring the need for ongoing adaptation to effectively combat this highly mutable virus.</AbstractText><CopyrightInformation>© 2024 The Author(s). Influenza and Other Respiratory Viruses published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>Hye Won</ForeName><Initials>HW</Initials><AffiliationInfo><Affiliation>College of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rollon</LastName><ForeName>Rare</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>College of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Study of Emerging and Re-emerging Viruses, Korea Virus Research Institute, Institute for Basic Science (IBS), Daejeon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Se-Mi</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Center for Study of Emerging and Re-emerging Viruses, Korea Virus Research Institute, Institute for Basic Science (IBS), Daejeon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gil</LastName><ForeName>Juryeon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>College of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Study of Emerging and Re-emerging Viruses, Korea Virus Research Institute, Institute for Basic Science (IBS), Daejeon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casel</LastName><ForeName>Mark Anthony</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>College of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Study of Emerging and Re-emerging Viruses, Korea Virus Research Institute, Institute for Basic Science (IBS), Daejeon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>Hyunwoo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>College of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Study of Emerging and Re-emerging Viruses, Korea Virus Research Institute, Institute for Basic Science (IBS), Daejeon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Jeong Ho</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>College of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Study of Emerging and Re-emerging Viruses, Korea Virus Research Institute, Institute for Basic Science (IBS), Daejeon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>Seung-Gyu</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>College of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Study of Emerging and Re-emerging Viruses, Korea Virus Research Institute, Institute for Basic Science (IBS), Daejeon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazarte</LastName><ForeName>Josea Carmel</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>College of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Study of Emerging and Re-emerging Viruses, Korea Virus Research Institute, Institute for Basic Science (IBS), Daejeon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hee-Sung</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>College of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jun Hyoung</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Young Ki</ForeName><Initials>YK</Initials><AffiliationInfo><Affiliation>College of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Study of Emerging and Re-emerging Viruses, Korea Virus Research Institute, Institute for Basic Science (IBS), Daejeon, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>IBS-R801-D1</GrantID><Agency>Institute for Basic Sciences</Agency><Country /></Grant><Grant><GrantID>2020R1A5A2017476</GrantID><Agency>National Research Foundation of Korea</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Influenza Other Respir Viruses</MedlineTA><NlmUniqueID>101304007</NlmUniqueID><ISSNLinking>1750-2640</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000090982">BNT162 Vaccine</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007117" MajorTopicYN="Y">Immunization, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090982" MajorTopicYN="N">BNT162 Vaccine</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antibody responses</Keyword><Keyword MajorTopicYN="N">bivalent</Keyword><Keyword MajorTopicYN="N">monovalent</Keyword><Keyword MajorTopicYN="N">omicron sublineages</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>7</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>7</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>5</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39377176</ArticleId><ArticleId IdType="pmc">PMC11459205</ArticleId><ArticleId IdType="doi">10.1111/irv.70000</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
World Health Organization (WHO)
, “Statement on the Update of WHO's Working Definitions and Tracking System for SARS‐CoV‐2 Variants of Concern and Variants of Interest,” (2023), accessed October 10, 2023, https://www.who.int/news/item/16‐03‐2023‐statement‐on‐the‐update‐of‐who‐s‐working‐definitions‐and‐tracking‐system‐for‐sars‐cov‐2‐variants‐of‐concern‐and‐variants‐of‐interest.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10153606</ArticleId><ArticleId IdType="pubmed">37062542</ArticleId></ArticleIdList></Reference><Reference><Citation>He X., Hong W., Pan X., Lu G., and Wei X., “SARS‐CoV‐2 Omicron Variant: Characteristics and Prevention,” MedComm 2, no. 4 (2021): 838–845, 10.1002/mco2.110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mco2.110</ArticleId><ArticleId IdType="pmc">PMC8693031</ArticleId><ArticleId IdType="pubmed">34957469</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia S., Wang L., Zhu Y., Lu L., and Jiang S., “Origin, Virological Features, Immune Evasion and Intervention of SARS‐CoV‐2 Omicron Sublineages,” Signal Transduction and Targeted Therapy 7, no. 1 (2022): 241, 10.1038/s41392-022-01105-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-01105-9</ArticleId><ArticleId IdType="pmc">PMC9295084</ArticleId><ArticleId IdType="pubmed">35853878</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis‐Gardner M. E., Lai L., Wali B., et al., “Neutralization Against BA.2.75.2, BQ.1.1, and XBB From mRNA Bivalent Booster,” The New England Journal of Medicine 388, no. 2 (2023): 183–185, 10.1056/NEJMc2214293.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2214293</ArticleId><ArticleId IdType="pmc">PMC9812288</ArticleId><ArticleId IdType="pubmed">36546661</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurhade C., Zou J., Xia H., et al., “Low Neutralization of SARS‐CoV‐2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by Parental mRNA Vaccine or a BA.5 Bivalent Booster,” Nature Medicine 29, no. 2 (2023): 344–347, 10.1038/s41591-022-02162-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02162-x</ArticleId><ArticleId IdType="pubmed">36473500</ArticleId></ArticleIdList></Reference><Reference><Citation>
Neherlab
, “Variant Report 2023‐9‐28,” (2023), accessed October 12, 2023, https://reports/variant_report_latest_draft.md.</Citation></Reference><Reference><Citation>
covSPECTRUM
, (2023), accessed October 12, 2023, https://cov‐spectrum.org/explore/World/AllSamples/Past2M/variants?variantQuery=%21nextcladePangoLineage%3AXBB*+%26+%21405G&amp;.</Citation></Reference><Reference><Citation>
Global Initiative on Sharing All Influenza Data (GISAID)
, (2023), accessed October 12, 2023, https://gisaid.org/hcov‐19‐variants‐dashboard/.</Citation></Reference><Reference><Citation>
cov‐lineages.org
, (2023), accessed October 12, 2023, https://cov‐lineages.org/lineage_list.html.</Citation></Reference><Reference><Citation>Tan C. Y., Chiew C. J., Pang D., et al., “Effectiveness of Bivalent mRNA Vaccines Against Medically Attended Symptomatic SARS‐CoV‐2 Infection and COVID‐19‐Related Hospital Admission Among SARS‐CoV‐2‐Naive and Previously Infected Individuals: A Retrospective Cohort Study,” Lancet Infectious Diseases S1473‐3099, no. 23 (2023): 003730, 10.1016/S1473-3099(23)00373-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00373-0</ArticleId><ArticleId IdType="pubmed">37543042</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D., Staropoli I., Michel V., et al., “Distinct Evolution of SARS‐CoV‐2 Omicron XBB and BA.2.86/JN.1 Lineages Combining Increased Fitness and Antibody Evasion,” Nature Communications 15, no. 1 (2024): 2254, 10.1038/s41467-024-46490-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-46490-7</ArticleId><ArticleId IdType="pmc">PMC10938001</ArticleId><ArticleId IdType="pubmed">38480689</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y., Yisimayi A., Jian F., et al., “BA.2.12.1, BA.4 and BA.5 Escape Antibodies Elicited by Omicron Infection,” Nature 608, no. 7923 (2022): 593–602, 10.1038/s41586-022-04980-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04980-y</ArticleId><ArticleId IdType="pmc">PMC9385493</ArticleId><ArticleId IdType="pubmed">35714668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Iketani S., Li Z., et al., “Alarming Antibody Evasion Properties of Rising SARS‐CoV‐2 BQ and XBB Subvariants,” Cell 186, no. 2 (2023): 279–286, 10.1016/j.cell.2022.12.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.12.018</ArticleId><ArticleId IdType="pmc">PMC9747694</ArticleId><ArticleId IdType="pubmed">36580913</ArticleId></ArticleIdList></Reference><Reference><Citation>Uraki R., Ito M., Furusawa Y., et al., “Humoral Immune Evasion of the Omicron Subvariants BQ.1.1 and XBB,” Lancet Infectious Diseases 23, no. 1 (2023): 30–32, 10.1016/S1473-3099(22)00816-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00816-7</ArticleId><ArticleId IdType="pmc">PMC9729000</ArticleId><ArticleId IdType="pubmed">36495917</ArticleId></ArticleIdList></Reference><Reference><Citation>
Korea Disease Control and Prevention Agency (KDCA)
, accessed September 22, 2023, https://www.kdca.go.kr/contents.es?mid=a20107030000.</Citation></Reference><Reference><Citation>Jeong H. W., Kim S.‐M., Jung M. K., et al., “Enhanced Antibody Responses in Fully Vaccinated Individuals Against Pan‐SARS‐CoV‐2 Variants Following Omicron Breakthrough Infection,” Cell Reports Medicine 3, no. 10 (2022): 100764, 10.1016/j.xcrm.2022.100764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100764</ArticleId><ArticleId IdType="pmc">PMC9482837</ArticleId><ArticleId IdType="pubmed">36182684</ArticleId></ArticleIdList></Reference><Reference><Citation>Chenchula S., Amerneni K. C., Ghanta M. K., et al., “Clinical Virology and Effect of Vaccination and Monoclonal Antibodies Against Highly Infectious SARS‐CoV‐2 Omicron Subvariant BF.7 (BA.5.2.1.7): A Systematic Review,” Virology 7, no. 548 (2023): 38–43, 10.1016/j.virol.2023.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2023.04.007</ArticleId><ArticleId IdType="pmc">PMC10197433</ArticleId><ArticleId IdType="pubmed">37229914</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates T. A., McBride S. K., Leier H. C., et al., “Vaccination Before or After SARS‐CoV‐2 Infection Leads to Robust Humoral Response and Antibodies That Effectively Neutralize Variants,” Science Immunology 7, no. 68 (2022): eabn8014, 10.1126/sciimmunol.abn8014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abn8014</ArticleId><ArticleId IdType="pmc">PMC8939472</ArticleId><ArticleId IdType="pubmed">35076258</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Muecksch F., Schaefer‐Babajew D., et al., “Naturally Enhanced Neutralizing Breadth Against SARS‐CoV‐2 One Year After Infection,” Nature 595, no. 7867 (2021): 426–431, 10.1038/s41586-021-03696-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03696-9</ArticleId><ArticleId IdType="pmc">PMC8277577</ArticleId><ArticleId IdType="pubmed">34126625</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L., Lin S., Chen Z., et al., “Targetable Elements in SARS‐CoV‐2 S2 Subunit for the Design of Pan‐Coronavirus Fusion Inhibitors and Vaccines,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 197, 10.1038/s41392-023-01472-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-023-01472-x</ArticleId><ArticleId IdType="pmc">PMC10170451</ArticleId><ArticleId IdType="pubmed">37164987</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds C. J., Pade C., Gibbons J. M., et al., “Immune Boosting by B.1.1.529 (Omicron) Depends on Previous SARS‐CoV‐2 Exposure,” Science 377, no. 6603 (2022): eabq1841, 10.1126/science.abq1841.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abq1841</ArticleId><ArticleId IdType="pmc">PMC9210451</ArticleId><ArticleId IdType="pubmed">35699621</ArticleId></ArticleIdList></Reference><Reference><Citation>Uversky V. N., Redwan E. M., Makis W., and Rubio‐Casillas A., “IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS‐CoV‐2 Spike Protein,” Vaccines (Basel) 11, no. 5 (2023): 991, 10.3390/vaccines11050991.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11050991</ArticleId><ArticleId IdType="pmc">PMC10222767</ArticleId><ArticleId IdType="pubmed">37243095</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>